Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-03-11
2008-03-11
Andres, Janet L. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S301000, C514S318000, C514S338000, C546S194000, C546S114000, C546S276400, C544S238000
Reexamination Certificate
active
10773344
ABSTRACT:
A compound represented by the general formula (1):in-line-formulae description="In-line Formulae" end="lead"?Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4 (1)in-line-formulae description="In-line Formulae" end="tail"?wherein R1and R2are hydrogen atoms or the like; Q1is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q2is a single bond or the like; Q3is a groupin which Q5is an alkylene group having 1 to 8 carbon atoms, or the like; and T0and T1are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof.The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.
REFERENCES:
patent: 5668159 (1997-09-01), Jin et al.
patent: 5707994 (1998-01-01), Ikeda et al.
patent: 5811441 (1998-09-01), Olson et al.
patent: 5849736 (1998-12-01), Wityak et al.
patent: 5852045 (1998-12-01), Askew et al.
patent: 6054065 (2000-04-01), Uang et al.
patent: 6300330 (2001-10-01), Stocker et al.
patent: 6359134 (2002-03-01), Tawada et al.
patent: 6525042 (2003-02-01), Kobayashi et al.
patent: 6747023 (2004-06-01), Kobayashi et al.
patent: 2005/0020645 (2005-01-01), Ohta et al.
patent: 0 602 306 (1994-06-01), None
patent: 0 937 711 (1999-08-01), None
patent: 0 937 723 (1999-08-01), None
patent: 0 947 510 (1999-10-01), None
patent: 1 102 766 (2001-05-01), None
patent: 2000-86659 (2000-03-01), None
patent: 2000-302765 (2000-10-01), None
patent: 2001-11071 (2001-01-01), None
patent: WO 86/07257 (1986-12-01), None
patent: WO 93/10022 (1993-05-01), None
patent: WO 94/20062 (1994-09-01), None
patent: WO 94/21599 (1994-09-01), None
patent: WO 92/04017 (1995-03-01), None
patent: WO 96/10022 (1996-04-01), None
patent: WO 96/26187 (1996-08-01), None
patent: WO 96/31501 (1996-10-01), None
patent: WO 96/40100 (1996-12-01), None
patent: WO 97/06802 (1997-02-01), None
patent: WO 97/10853 (1997-03-01), None
patent: WO 97/29104 (1997-08-01), None
patent: WO 97/38984 (1997-10-01), None
patent: WO 98/06705 (1998-02-01), None
patent: 98/21188 (1998-05-01), None
patent: WO 98/21188 (1998-05-01), None
patent: WO 98/35956 (1998-08-01), None
patent: WO 98/45262 (1998-10-01), None
patent: WO 98/54164 (1998-12-01), None
patent: WO 98/57952 (1998-12-01), None
patent: WO 99/00121 (1999-01-01), None
patent: WO 99/00126 (1999-01-01), None
patent: WO 99/00127 (1999-01-01), None
patent: 99/06371 (1999-02-01), None
patent: 99/09027 (1999-02-01), None
patent: WO 99/06371 (1999-02-01), None
patent: WO 99/09027 (1999-02-01), None
patent: WO 99/20606 (1999-04-01), None
patent: WO 99/32225 (1999-07-01), None
patent: 99/51614 (1999-10-01), None
patent: WO 99/54308 (1999-10-01), None
patent: WO 99/57099 (1999-11-01), None
patent: WO 99/57112 (1999-11-01), None
patent: WO 99/57113 (1999-11-01), None
patent: 00/00498 (2000-01-01), None
patent: WO 00/06570 (2000-02-01), None
patent: WO 00/09480 (2000-02-01), None
patent: WO 00/39092 (2000-07-01), None
patent: WO 00/39111 (2000-07-01), None
patent: WO 00/39117 (2000-07-01), None
patent: WO 00/39118 (2000-07-01), None
patent: WO 00/47573 (2000-08-01), None
patent: WO 00/59913 (2000-10-01), None
patent: WO 00/64902 (2000-11-01), None
patent: WO 00/71516 (2000-11-01), None
patent: WO 00/76942 (2000-12-01), None
patent: WO 00/76971 (2000-12-01), None
patent: WO 00/78749 (2000-12-01), None
patent: WO 01/07440 (2001-02-01), None
patent: WO 01/17990 (2001-03-01), None
patent: WO 01/19788 (2001-03-01), None
patent: WO 01/19795 (2001-03-01), None
patent: WO 01/19798 (2001-03-01), None
patent: WO 01/38309 (2001-05-01), None
patent: WO 01/64642 (2001-09-01), None
patent: WO 01/64643 (2001-09-01), None
patent: WO 01/74774 (2001-10-01), None
patent: WO 02/02519 (2002-01-01), None
patent: WO 02/26712 (2002-04-01), None
patent: WO 02/26720 (2002-04-01), None
patent: WO 02/26734 (2002-04-01), None
patent: WO 02/42270 (2002-05-01), None
patent: WO 02/060859 (2002-08-01), None
patent: WO 02/079145 (2002-10-01), None
patent: WO 02/102380 (2002-12-01), None
patent: WO 03/026652 (2003-04-01), None
patent: WO 03/045912 (2003-06-01), None
patent: WO 03/048081 (2003-06-01), None
patent: WO 03/048158 (2003-06-01), None
patent: 03/099276 (2003-12-01), None
Hcaplus 68:22392.
Pandey, B. R., et al., “Interrelationship between anticonvulsant and enzyme inhibitor properties on N-methyl-N-Å2-(1-arylthiocarbamido) cyclopentyÜnitrobenzamides,” Pharacological Research Communications, Italian Pharmacological Society, IT, vol. 13, No. 1, 1981, pp. 65-74, XP002977669.
Bied, C., et al., “Chiral amino-urea derivatives of (1R,2R)-1,2-diaminocyclohexane as ligands in the ruthenium catalyzed asymmetric reduction of aromatic ketones by hydride transfer,” Tetrahedron: Asymmetry, 12(2), 2001, pp. 329-336, XP004230915.
Smith, P. J., et al.,“Substrate-specific catalysis via ion pairs,” Angewandle Chemie Int. Ed. Engl., 1993, 32(11), pp. 1648-1650, 1993, XP002384367.
U.S. Appl. No. 11/217,837, filed Sep. 2, 2005, Yoshino et al.
U.S. Appl. No. 10/539,995, filed Jun. 22, 2005, Nakamoto, et al.
U.S. Appl. No. 10/540,259, filed Jun. 23, 2005, Ohta, et al.
Abstracts of Papers, Part 1, 218thACS National Meeting, 0-8412-3685-2, Medi 29 and Medi 199, 3 pages, Aug. 22-26, 1999.
Abstracts of Papers, Part 2, 219thACS National Meeting, 0-8412-3731-X, Medi 187, 2 pages, Mar. 26-30, 2000.
Abstracts of Papers, Part 1, 220thACS National Meeting, 0-8412-3749-2, Medi 289 and Medi 328, 3 pages, Aug. 20-24, 2000.
Abstracts of Papers, Part 2, 221thACS National Meeting, 0-8412-3788-3, Medi 128 (with poster), 3 pages, Apr. 1-5, 2001.
Abstracts of Papers, Part 2, 226thACS National Meeting, 0-8412-3889-8, Medi 79 (with poster), 3 pages, Sep. 7-11, 2003.
S. M. Sheehan, et al., Bioorganic & Medicinal Chemistry Letters, vol. 13, pp. 2255-2259, “A Four Component Coupling Strategy for the Synthesis of D-Phenylglycinamide-Derived Non-Covalent Factor Xa Medi 289Inhibitors”, 2003.
Y. K. Yee, et al., J. Med. Chem., vol. 43, No. 5, pp. 873-882, “N2-Aroylanthranilamide Inhibitores of Human Factor Xa”, 2000.
D. K. Herron, et al., J. Med. Chem., vol. 43, No. 5, pp. 859-872, “1,2-Dibenzamidobenzene Inhibitors of Human Factor Xa”, 2000.
C. Wu, et al., Bioorganic & Medicinal Chemistry, vol. 5, No. 10, pp. 1925-1934, “Stereochemical Influence on the Stability of Radio-Metal Complexes In Vivo. Synthesis and Evaluation of the Four Stereoisomers of 2-(p-Nitrobenzyl)-Trans-CyDTPA”, 1997.
Y.-L. Chou, et al., Bioorganic & Medicinal Chemistry Letters, vol. 13, pp. 507-511, “Structure-Activity Relationships of Substituted Benzothiophene-Anthranilamide Factor Xa Inhibitors”, 2003.
M. Adler, et al., Biochemistry, vol. 41, No. 52, pp. 15514-15523, “Crystal Structures of Two Potent Nonamidine Inhibitors Bound to Factor Xa”, 2000.
J. J. Masters, et al., J. Med. Chem., vol. 43, No. 11, pp. 2087-2092, “Non-Amidine-Containing 1,2-Dibenzamidobenzene Inhibitors of Human Factor Xa With Potent Anticoagulant and Antithrombotic Activity”, 2000.
M. R. Wiley, et al., J. Med. Chem., vol. 43, No. 5, pp. 883-899, “Structure-Based Design of Potent, Amidine-Derived Inhibitors of Factor XA: Evaluation of Selectivity, Anticoagulant Activity, and Antithrombotic Activity”, 2000.
Jan J. Sigma, et al., “The Ideal Anti-Thrombotic Drug,” Thrombosis Research, Erratum, vol. 68, pp. 507-512, 1992.
Susan Elodi, et al., “Optimization of Conditions for the Catalytic Effect of the Factor IXa—Factor VIII Complex: Probable Role of the Co
Haginoya Noriyasu
Kanno Hideyuki
Kobayashi Syozo
Komoriya Satoshi
Mochizuki Akiyoshi
Andres Janet L.
Daiichi Pharmaceutical Co. Ltd.
Oblon & Spivak, McClelland, Maier & Neustadt P.C.
Robinson Binta
LandOfFree
Diamine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diamine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diamine derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3913376